TABLE 3.
Percent susceptible to cefiderocol, ceftazidime-avibactam, eravacycline, and comparators by phylogroup among 343 carbapenem-resistant Escherichia coli clinical isolates
| Agentb,c | No. total susceptible (% of 343) | Phylogroupa and no. susceptible (%) |
Pd | |||||
|---|---|---|---|---|---|---|---|---|
| A (n = 54) | B1 (n = 46) | B2 (n = 105) | C (n = 28) | D (n = 66) | F (n = 42) | |||
| CFDC | 315 (92) | 45 (83) | 39 (85) | 101 (96) | 23 (82) | 66 (100) | 39 (93) | 0.002 |
| CZA | 281 (82) | 41 (76) | 24 (52) | 98 (93) | 19 (68) | 59 (89) | 38 (91) | <0.001 |
| ERV | 335 (98) | 50 (93) | 45 (98) | 105 (100) | 27 (96) | 64 (97) | 42 (100) | |
| MEM | 203 (59) | 24 (44) | 18 (39) | 68 (65) | 12 (43) | 43 (65) | 36 (86) | <0.001 |
| IPM | 100 (29) | 9 (17) | 5 (11) | 43 (41) | 2 (7) | 27 (41) | 14 (33) | <0.001 |
| ETP | 15 (4) | 2 (4) | 3 (7) | 6 (6) | 3 (11) | 0 (0) | 1 (2) | |
| GEN | 189 (55) | 29 (54) | 19 (41) | 69 (66) | 10 (36) | 38 (57) | 39 (93) | 0.046 |
| TZP | 72 (21) | 4 (7) | 6 (13) | 32 (31) | 4 (14) | 19 (29) | 0 (0) | 0.007 |
| AMK | 269 (78) | 44 (82) | 28 (61) | 82 (78) | 24 (86) | 57 (86) | 32 (76) | |
| LVX | 62 (18) | 5 (9) | 10 (22) | 18 (17) | 2 (7) | 20 (30) | 7 (17) | 0.047 |
| TGC | 340 (99) | 52 (96) | 46 (100) | 105 (100) | 28 (100) | 65 (99) | 42 (100) | |
| CAZ | 36 (11) | 5 (9) | 6 (13) | 11 (11) | 0 (0) | 9 (14) | 5 (12) | |
| MIN | 231 (67) | 29 (54) | 25 (54) | 89 (85) | 15 (54) | 43 (65) | 28 (67) | <0.001 |
a
Phylogroups shown are only those with n > 3 (phylogroup E: n = 2 [0.6%]).
b
Abbreviations: AMK, amikacin; CFDC, cefiderocol; CAZ, ceftazidime; CZA, ceftazidime-avibactam; ERV, eravacycline; ETP, ertapenem; GEN, gentamicin; IPM, imipenem; LVX, levofloxacin; MEM, meropenem; MIN, minocycline; TZP, piperacillin-tazobactam; TGC, tigecycline.
c
CL, colistin: not shown; all isolates resistant.
d
P values, as determined by chi-square test for six-group comparisons across phylogroup, are shown where P < 0.05.